Latest Breaking News On - Rituximab biosimilar - Page 1 : comparemela.com

Biosimilar HLX01 Demonstrates Bioequivalence With Rituxan in DLBCL

A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).

International prognostic indexChina national medical products administrationWorld health organizationBiomed centralNational medical products administrationWorld healthDiffuse largeb cell lymphomaRituximab biosimilarR chopTh chop

Chronic Lymphocytic Leukemia (CLL) Report 2021: Treatments, Epidemiology, Marketed Drugs, Pipeline Drugs, Regulatory Events, Clinical Trials, Drug Assessment, Future Trends

Chronic Lymphocytic Leukemia (CLL) Report 2021: Treatments, Epidemiology, Marketed Drugs, Pipeline Drugs, Regulatory Events, Clinical Trials, Drug Assessment, Future Trends
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Innovent rituximabRituximab biosimilarLaura woodE st office hours callOffice hours callLymphocytic leukemiaTopics coveredCalquence approved for leukemiaApproves more drugs for cancerChronic lymphocytic leukemiaSmall cell lymphocytic lymphomaSenior managerFree callHours callலாரா மரம்ஏ ஸ்டம்ப் அலுவலகம் மணி அழைப்பு